Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Eisai Inc.

Shigeki Hibi

Katsuya Tagami

Kouichi Kikuchi

Hiroyuki Yoshimura

Mitsuo Nagai

Takashi Yamanaka

Hisashi Shibata

Yorihisa Hoshino

Takayuki Hida

Isao Yamatsu

Yasushi Okamoto

Shinya Abe

Yoshinori Takahashi

Makoto Okita

Kogyoku Shin

Seiko Higashi

Motohiro Soejima

Ieharu Hishinuma

Koichi Kikuchi

Junichi Nagakawa

Tatsuya Yoshiuchi

Mitsuhiro Ino

Kenji Tai

Seiichi Kobayashi

Naoki Tokuhara

Naoki Kobayashi

Tetsuya Hirakawa

Kazuo Hirota

Makoto Asada

Norimasa Miyamoto

Aichi Ogasawara

Mutsuko Ono

Shuhei Miyazawa

Tetsuya Kawahara

Masanobu Shinoda

Masanori Mizuno

Takashi Mori

Hirotoshi Numata

Toshihiko Kaneko

Takeshi Suzuki

Shigeru Souda

Yoshimasa Machida

Seiichiro Nomoto

Takashi Sato

Manabu Murakami

Kouichi Katayama

Takashi Inoue

Kiyoshi Oketani

Hiroshi Shirota

Kenichi Chiba

Hideki Ono

Kaname Miyamoto

Ryoichi Hashida

Masayuki Tanaka

Hideto Ohhara

Masaki Goto

Hideki Sakurai

Mutsuko Tabata

Yumiko Nagasaka

Hiromitsu Yokohama

Tsutomu Yoshimura

Yasunori Akita

Koichi Katayama

Masae Fujisawa

Tohru Horie

Koukichi Harada

Koichi Abe

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula or a salt thereof. Wherein Rdenotes a hydrogen atom, a Calkyl group, a Calkoxy group and the like; Rdenotes a halogen atom, a cyano group, a nitro group, a Calkyl group, a Calkenyl group, Calkynyl group and the like; Rdenotes a Caromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may have a substituent; and X, Y and X are independent of each other and each denotes N or CR(wherein Rdenotes a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally halogenated Calkyl group and the like) and, in this case, at least two of X, Y and Z denote CR.

Imidazo[1,2-b]pyridazine compound

Compounds represented by the general formula: [wherein Rrepresents methoxy, ethyl, methylthio, etc., R, Rand Reach represent hydrogen, a halogen, etc., Rand Reach represent &#x2014;X&#x2014;X&#x2014;X(wherein Xrepresents a single bond or &#x2014;CO&#x2014;, Xrepresents a single bond, &#x2014;NR, etc. and Xand Reach represent hydrogen, Calkyl, etc.), and Ar represents phenyl, pyridyl, etc.], salts thereof and hydrates of the foregoing.

Pyrazolo[1,5-a]pyridines and medicines containing the same

A compound represented by the formula: [wherein Ris methoxy, methylthio, ethyl, etc.; Rand Rare each independently cyclopropylmethyl, (4-tetrahydropyranyl)methyl, etc.; and two of R, Rand Rare Calkoxy while the remaining one is methoxymethyl, etc.], a salt thereof, or a hydrate of the foregoing. This compound has excellent antagonism against corticotropin-releasing factor receptor.

7-phenylpyrazolopyridine compounds

Pyrazolo[1,5-a] pyridines and medicines containing the same

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof,wherein Ris a hydrogen atom, etc.; Ris a hydrogen atom, etc.; M' represents a hydrogen atom, a halogen atom or a Calkyl group; R&#x2032; represents a hydrogen atom or a Calkyl group; and W&#x2032; represents a phenyl group, pyridyl group, thienyl group, or furyl group, each being optionally substituted; and a pharmacologically acceptable salt thereof or hydrates thereof.

Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof.Wherein A, B and D are the same as or different from each other and each represents a group represented by the formula &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each represents a Calkyl group etc.), &#x2014;NR&#x2014; (wherein Rrepresetns hydrogen etc.) etc.; E and G are the same as or different from each other and each represents a group represented by the formula &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each represents hydrogen etc.; and p represents an integer of 0, 1 or 2); J represents a carbon atom or nitrogen atom, each substituted with Calkyl group optionally substituted with a halogen atom, etc.; K and L are the same as or different from each other and each represents carbon atom or nitrogen atom; M means hydrogen, a halogen atom, an optionally substituted Calkyl group etc.; and the partial structuremeans a single or double bond.

Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof,wherein

Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I):wherein A represents, for example, a heteroaryl group which contains at least one nitrogen atom and may have a substituent, B represents, for example, a heteroarylene group, a &#x2014;CONH&#x2014; group or a group represented by the formula &#x2014;CR&#x2550;CR&#x2014; in which Rand Rrepresents H, a lower alkyl group or the like, D represents an arylene group, a heteroarylene group or the like, n1 stands for 0 or 1, M represents, for example, a hydroxyl group or a lower alkoxy group; or a physiologically acceptable salt thereof. As a retinoic-related compound replacing retinoic acid, it permits the provision of a preventive and/or therapeutic for various diseases.

Heterocycle-containing carboxylic acid derivative and drug containing the same

Mono- or polyenic carboxylic acid derivatives

Carboxylic acid derivatives having fused rings

Growing community of inventors

Tsukuba, Japan

Shigeki Hibi